Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

ClinicalTrials.gov ID: NCT02934503

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02934503. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Pembrolizumab and Dynamic PD-L1 Expression in Extensive Stage Small Cell Lung Cancer (SCLC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is to assess the efficacy of pembrolizumab added to concurrent chemotherapy with or without radiation therapy in patients with small cell lung cancer (SCLC).

Study identification

NCT ID: NCT02934503
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: NYU Langone Health; Other
Enrollment: 5 participants

Conditions and interventions

Conditions

Small Cell Lung Cancer (SCLC)

Interventions

Pembrolizumab Biological
Cisplatin Drug
Carboplatin Drug
Etoposide Drug
Radiation therapy Radiation

Biological · Drug · Radiation

Eligibility (public fields only)

Age range: 19 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 23, 2017 (Actual)
Primary completion: Oct 1, 2019 (Actual)
Completion: Oct 1, 2019 (Actual)
Last update posted: Nov 16, 2021

2017 – 2019

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York	New York	10016	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02934503, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 16, 2021 · Synced Nov 14, 2026